Figure_2.tif (201.71 kB)
Effect of pioglitazone on endogenous beta-cell regeneration in MIP-luc mice.
figure
posted on 2013-06-06, 00:50 authored by Hao Yin, Soo-Young Park, Xiao-Jun Wang, Ryosuke Misawa, Eric J. Grossman, Jing Tao, Rong Zhong, Piotr Witkowski, Graeme I. Bell, Anita S. Chong(a) Overview of experimental design. Following treatment with STZ, diabetic MIP-luc mice (BG >400 mg/dl) received an insulin implant at week 0, 4 and 8 post-STZ (grey arrows). Mice were divided into two groups at 6 weeks post-STZ, receiving CMC (No Rx) or Pio (25 mg/kg; 5X/week; Pio). BG (b) and the bioluminescent signal from the endogenous beta-cells (c) were monitored every week. Data are presented as mean (N = 5/group) ± standard error of mean (SEM). (d) Bioluminescent signal at week 12 post-STZ in control (No Rx) or Pio-treated groups as a mean percentage of bioluminescence prior to STZ treatment.
History
Usage metrics
Categories
Keywords
developmental biologyOrganism developmentregenerationimmunologyImmunologic subspecialtiestransplantationModel organismsAnimal modelsmouseClinical immunologyImmune responseimmunomodulationDrugs and devicesClinical pharmacologyEndocrinologyDiabetic endocrinologyDiabetes mellitus type 1Diabetes mellitus type 2surgeryTransplant surgerypioglitazoneendogenousbeta-cellmip-luc
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC